Operator

Welcome to BioGaia Q1 report for 2026.

[Operator Instructions]

Now I will hand the conference over to CEO, Theresa Agnew, and CFO, Alexander Kotsinas. Please go ahead.

Theresa Agnew
CEO & President

This is Theresa Agnew, CEO of BioGaia, and we are here to present our Q1 2026 results. So in terms of the highlights, we have growth, excluding currency effects, of 15%. Our EBIT margin for the quarter is 27%, and overall, our free cash flow is SEK 67 million. Our net sales reached SEK 373 million. And as I said, organic growth of 15%, 2% growth when you include currency effects. By region, our Asia-Pacific region increased by 6%, excluding currency effects. In the Americas, we increased by 12%, excluding currency effects. And for Europe, Middle East, Africa, we increased by 24%, excluding currency effects. Our operating profit for the quarter was around SEK 101 million, which is 4% growth. And our EBIT margin, as I said, was 27% comparing to 27% same quarter last year.

To remind you of our company strategy, we have 3 strategic pillars: Grow the core, where we focus on growing our core health areas, gut health of which colic is apart, oral health and immune health. Our second strategic pillar is what we call expansion through direct markets, so focusing on growing our current 12 direct markets. And focusing our marketing and selling and investment activities in those markets to drive growth ahead of market.

And our